m***T
发帖数: 11058 | 1 NGS市场又要热闹了。
http://www.bio-itworld.com/news/09/17/12/Sequencing-giants-BGI-
Sequencing Giants BGI and Complete Genomics Announce Merger Agreement
By Bio-IT World Staff
September 17, 2012 | In a stunning move for the genomics industry, two
leading DNA sequencing service providers – China’s BGI and Complete
Genomics – have entered into a definitive merger agreement.
In a prospective deal worth some $117 million, BGI Shenzhen has tendered an
offer of $3.15/share for all of Complete’s outstanding shares. The price is
a 54% premium on Complete’s stock price on June 4, 2012 – the last day
before Complete’s management announced it was exploring strategic business
alternatives in consultation with Jefferies & Company -- and an 18% premium
on the stock’s closing price last week.
In pre-market trading, Complete’s stock was up more than 10% to more than $
3/share on the merger news. However, it is a far cry from the $17 peak stock
price the company enjoyed at the end of 2010.
BGI's CEO Dr. Wang Jun commented: “Complete has developed a proprietary
whole human genome sequencing technology that, together with other
sequencing platforms used by BGI, will fit well with our research and
business requirements and position Complete to become an even more
successful global innovator. We look forward to growing the business to
improve medical research and, when clinical services are provided, support
better disease diagnosis with tools that can be used by doctors and
hospitals to treat their patients.”
Complete Genomics CEO Clifford Reid added: “We engaged in a thorough review
of a broad set of possible alternatives for the company, and we believe the
transaction with BGI represents the best outcome for our stockholders,
offering them liquidity and a premium value… The combination of the
companies' resources provides an opportunity to accelerate our vision of
providing researchers and physicians with the genomic information needed to
prevent, diagnose, and treat cancers and other genetic diseases.”
Goldman Sachs analyst Isaac Ro issued a note on the deal. The Complete
acquisition accelerates BGI’s search for a U.S. sequencing base, says Ro,
“giving BGI an immediate infrastructure and service offering that will
complement the facilities in China.”
Ro sees the merger having little immediate impact on Illumina’s business.
“Our recent checks have suggested that BGI has been running its [Illumina]
lab well below full capacity, suggesting the incremental impact to demand
will not be material even though BGI represents a sizable percentage of the
installed base.”
He adds that visits to BGI “have shown significant infrastructure tied to [
Illumina] technology (informatics and workflow) that we don't believe will
be shut down as a result of this deal. Rather, we expect that BGI will
continue to run their existing [Illumina] labs in China and the [Complete
Genomics] facility in San Francisco together.”
Deal Details
BGI and Complete Genomics have emerged as the two of the leading providers
of genome sequencing services to academia and industry. In addition,
Illumina offers an extensive network of genome sequencing contractors, and
many other companies and service providers offer various sequencing
capabilities, including Expression Analysis, GATC Biotech, Seqwright,
Beckman Coulter and Perkin Elmer. Recently, Complete published details of
its Long Fragment Read technology, offering unparalleled sequencing accuracy
. While Complete has signaled a strong move into the clinical sequencing
market, the company was struggling to sustain a profitable business, and
this summer engaged Jefferies & Company to advise it on strategic
alternatives.
BGI offers a large a la carte menu of sequencing services, including exome
and transcriptome sequencing in addition to whole-genome sequencing, on
essentially any organism. The organization hosts most of its sequencing
operation in Hong Kong, which facilitates the transfer of samples and
results. By contrast, from its launch, Complete Genomics elected to
specialize in whole-genome sequencing of human samples.
BGI Americas, the U.S.-based subsidiary of BGI, will launch a tender offer
to purchase all outstanding shares of Complete’s common stock. The proposed
merger has been unanimously approved by Complete's board of directors.
Complete will also be provided with up to $30 million in bridge financing
for its operations following the signing of the merger agreement.
All of Complete's directors and executive officers as well as certain other
major stockholders, who collectively own approximately 17.5% of the
outstanding common stock of Complete, have agreed to tender all of their
shares pursuant to the tender offer. The merger is expected to be wrapped up
in early 2013, although it is contingent on the approval of certain
governmental authorities in China, as well as the satisfaction of other
customary conditions. | y***i
发帖数: 11639 | 2 牛。要是成功的话算是占领了一块战略要地。
an
is
【在 m***T 的大作中提到】
: NGS市场又要热闹了。
: http://www.bio-itworld.com/news/09/17/12/Sequencing-giants-BGI-
: Sequencing Giants BGI and Complete Genomics Announce Merger Agreement
: By Bio-IT World Staff
: September 17, 2012 | In a stunning move for the genomics industry, two
: leading DNA sequencing service providers – China’s BGI and Complete
: Genomics – have entered into a definitive merger agreement.
: In a prospective deal worth some $117 million, BGI Shenzhen has tendered an
: offer of $3.15/share for all of Complete’s outstanding shares. The price is
: a 54% premium on Complete’s stock price on June 4, 2012 – the last day
| D******9
发帖数: 2665 | | w***u
发帖数: 17713 | 4 基本上就是历史最低价按垃圾价买的，去年16-7块钱买的人就惨了。 |
|
